Sells and markets FDA-approved prescription medicines for skin conditions through specialty pharmacies, wholesalers and distributors.
10-K for FY2025, filed Mar 26, 2026We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration…View ↗
Specialized and differentiated access and distribution model. We have a specialized and differentiated access and distribution network of…View ↗
We primarily sell our prescription products to specialty pharmacies, independent wholesalers, and distributors with limited sales through…View ↗
Journey sells prescription products to specialty pharmacies, wholesalers and distributors, with product sales tied to delivery when customers receive the goods. It also earns revenue from supplying Amzeeq to Cutia and royalties on Cutia’s Amzeeq sales in China.
10-K for FY2025, filed Mar 26, 2026Revenue RecognitionView ↗
We primarily sell our prescription products to specialty pharmacies, independent wholesalers, and distributors with limited sales through…View ↗
Other revenue for the year ended December 31, 2025 reflects the supply of Amzeeq to Cutia and sales-based royalties earned on the net sales…View ↗
10-K for FY2025, filed Mar 26, 2026
FY2025 revenue by product or service (Product revenue, net) ↗$61.9M
10-K for FY2025, filed Mar 26, 2026
$61.9M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Emrosi
Sold outright
10-K for FY2025, filed Mar 26, 2026 |
24% |
Emrosi, FY2025
$14.7M Sources
|
Sold outright |
|
Qbrexza
Sold outright
10-K for FY2025, filed Mar 26, 2026 |
41% |
Qbrexza, FY2025
$25M Sources
|
Sold outright |
|
Accutane
Sold outright
10-K for FY2025, filed Mar 26, 2026 |
21% |
Accutane, FY2025
$12.9M Sources
|
Sold outright |
|
Foam franchise products (Amzeeq & Zilxi)
Sold outright
10-K for FY2025, filed Mar 26, 2026 |
9.6% |
Foam franchise products (Amzeeq & Zilxi), FY2025
$5.9M Sources
|
Sold outright |
|
Other / legacy
Sold outright
|
4.5% |
Other / legacy, FY2025
$2.7M Sources
|
Sold outright |
Journey sells primarily to specialty pharmacies, independent wholesalers and distributors, including through traditional national wholesalers. Wholesalers and distributors supply retail drug chains, independent pharmacies and managed-care organizations.
10-K for FY2025, filed Mar 26, 2026We primarily sell our prescription products to specialty pharmacies, independent wholesalers, and distributors with limited sales through…View ↗
No. It lost $11.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$1.3MView ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
Open tableView ↗
8-K, filed Apr 21, 2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026View ↗
Flat. Revenue was $61.9M in FY2025, about the same as the $63.1M of FY2021.
From clinical testing to marketed treatment
The older report described a rosacea treatment in clinical testing; the latest says it was approved as Emrosi and that U.S. sales promotion began.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026On March 14, 2022, we dosed the first patient in our Phase 3 clinical trial evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg)…View ↗
On November 1, 2024, the FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed by…View ↗
Competes with Galderma
10-K for FY2025, filed Mar 26, 2026The tetracycline class of antibiotics (minocycline and doxycycline) are considered to be effective options for the treatment of…View ↗
Loading...